Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$6.97K$6.97Kno prior Q1 2017 on file Net Income-$618.92K-$618.92KN/M vs Q1 2017 EPS Diluted$0.00$0.00N/M vs Q1 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$590,751N/M Free Cash Flowderived-$599,720— Margins · derivedGross margin100.0%
Operating margin-18292.4%
Net margin-8877.2%
ended Mar 31, 2018 · filed May 18, 2018 · 48 d after period end